SCHEMBL16807289

SCHEMBL16807289

Cc1ccc(C(C(=O)c2ccccc2)c2ccc(F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
PTPN1 P18031 1/20 0.50
SLC6A9 P48067 1/20 0.48
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 4/20 0.48
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
ALPG P10696 1/20 0.45
HPGD P15428 1/20 0.45
ACHE P22303 1/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16781997 0.91 L3MBTL1 (0.73) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL2928039 0.90 L3MBTL1 (0.77) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL16807287 0.90 L3MBTL1 (0.77) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL16807290 0.86 L3MBTL1 (0.57) TDP1L3MBTL1PTPN1SLC6A9LMNA
SCHEMBL27890551 0.85 L3MBTL1 (0.63) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL9803692 0.84 TDP1 (0.73) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL15105761 0.84 L3MBTL1 (0.73) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL16781993 0.83 L3MBTL1 (0.61) TDP1L3MBTL1PTPN1SLC6A9LMNA
SCHEMBL16807277 0.83 L3MBTL1 (0.61) TDP1L3MBTL1PTPN1LMNASMN1; SMN2
SCHEMBL6708325 0.82 L3MBTL1 (0.59) TDP1L3MBTL1PTPN1SLC6A9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656947-B2 Process for creating carbon-carbon bonds using carbonyl compounds CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 2017-05-23 US disclosed
US-9656947-B2 Process for creating carbon-carbon bonds using carbonyl compounds CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 2017-05-23 US disclosed
EP-2858966-B1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NAT RECH SCIENT (FR) 2016-08-10 EP disclosed
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) 2015-06-18 US disclosed
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. R.S.) (FR) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166464-A1 PROCESS FOR CREATING CARBON-CARBON BONDS USING CARBONYL COMPOUNDS CBR3, CBR1, CYP4F3 TDP1 4876/4885L3MBTL1 4386/4885PTPN1 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.